Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysis

Clinicopathological Features Patients n (%) Clinicopathological Features Patients n (%)
Menopausal status   T  
Postmenopausal 15 (25) TIS 3 (5)
Premenopausal 39 (66) pTx 1 (2)
Unknown 5 (9) pT1 19 (33)
Histotype   pT2 22 (37)
Ductal invasive 45 (76) pT3 2 (3)
Lobular invasive 4 (7) pT4 12 (20)
Intraductal 3 (5) Diameter (mm)  
Inflammatory 4 (7) ≤ 10 mm 9 (15)
Other 3 (5) > 10 mm 42 (71)
Grading   Unknown 8 (14)
G1 7 (12)   
G2 18 (31) N  
G3 26 (44) pN1-3 20 (34)
Unknown 8 (13) pN4-10 9 (15)
Ki-67   pN > 10 4 (7)
0–15% 33 (56) Negative 19 (32)
16–25% 9 (15) Unknown 7 (12)
26–100% 14 (24) HER-2  
Unknown 3 (5) Positive 31 (53)
ER/PgR   Negative 28 (47)
ER+/PgR+ 38 (64)   
ER-/PgR- 12 (20) LVI  
ER+/PgR- 7 (12) Positive 27 (46)
ER-/PgR+ 1 (2) Negative 24 (41)
Unknown 1 (2) Unknown 8 (13)
  1. G, differentiation grade; G1-3, low, moderate or intermediate, high grade. ER, estrogen receptor alpha; PgR, progesterone receptor; T, tumor size; pT1, 0–2 cm; pT2, 2–5 cm; pT3, > 5 cm; pT4, ulcerated or attached; Tis, carcinoma in situ; pTX, primary tumor of unknown pT; N, node status; LVI, lymphovascular invasion; n, number of cases.